IDEAYA Presents Innovative Expansion Data for IDE397
IDEAYA Biosciences, Inc. (NASDAQ: IDYA) has presented promising interim data on IDE397, a targeted therapeutic for patients with methylthioadenosine phosphorylase (MTAP)-deletion in urothelial and lung cancer. These data were revealed during a late-breaking oral presentation. The results indicate that IDE397 has shown a substantial overall response rate (ORR) of approximately 33% among evaluable patients. This includes a complete response (CR) and eight partial responses (PRs) from a cohort of 27 heavily pre-treated patients.
Significant Clinical Findings for IDE397
The clinical trial reported that all nine responses were confirmed by RECIST 1.1 criteria. Among the MTAP-deletion urothelial cancer patients treated, the ORR was an impressive 40%, highlighting its potential in this group. Similarly, the drug demonstrated a ~38% ORR in patients with MTAP-deletion squamous non-small cell lung cancer (SqNSCLC).
Additional Benefits and Patient Outcomes
Patients treated with IDE397 also experienced long durations on therapy, with some remaining on treatment for over 250 days. Median duration of treatment (DOT) data indicated that over 6.2 months had elapsed without serious adverse events (SAEs) reported at the tested dose of 30 mg daily. The disease control rate (DCR) stood at an impressive 93%, reflecting the overall efficacy of the drug.
Safety Profile and Future Directions
Looking ahead, the company is planning to expand the Phase 1/2 study for IDE397 in combination with Trodelvy for MTAP-deletion urothelial cancer in the near future. IDEAYA is also slated to present a patient case study showcasing a rapid reduction in circulating tumor DNA (ctDNA) at the forthcoming ENA 2024 meeting.
Combination Therapies and Ongoing Research
In preclinical models, IDE397 has demonstrated pronounced and sustainable tumor regressions when paired with PRMT5 inhibitors, further reinforcing IDEAYA's commitment to advancing combination therapies. The company is actively exploring several potential combinations as it progresses towards Phase 2 trials, and is focused on addressing cancers that currently lack FDA-approved treatment options.
Addressing Unmet Medical Needs
The presence of MTAP-deletion solid tumors represents a significant unmet need in oncology, with estimates suggesting around 48,000 patients annually in the U.S. affected by these conditions, particularly in urothelial and non-small cell lung cancers. IDEAYA's active pipeline aims to fill this gap, as ongoing research explores other tumor types that may benefit from targeted therapies.
IDEAYA's Vision Moving Forward
In pursuit of addressing the challenges of MTAP-deletion tumors, IDEAYA has activated over 35 clinical trial sites worldwide, facilitating potentially rapid enrollment for ongoing trials aiming at expanding treatment options. The ultimate goal is to establish IDE397 as a first-in-class MAT2A inhibitor, paving the way for new standards in the treatment of challenging cancers.
Frequently Asked Questions
What is IDE397?
IDE397 is a potential first-in-class MAT2A inhibitor being developed by IDEAYA Biosciences for the treatment of MTAP-deletion solid tumors.
What are the key findings related to IDE397?
The drug has shown an overall response rate of approximately 33% in clinical trials, with a favorable safety profile and significant durations of response among treated patients.
How does IDEAYA plan to advance IDE397?
IDEAYA plans to expand the Phase 1/2 studies of IDE397 in combination with Trodelvy and provide deeper insights into its efficacy through ongoing clinical trials.
What cancers are targeted by IDE397?
IDE397 is primarily targeting MTAP-deletion urothelial cancer and non-small cell lung cancer, with prospects for further applications in pancreatic and gastric cancers.
Are there any ongoing trials for IDE397?
Yes, IDEAYA has multiple ongoing trials for IDE397, which include investigations into its efficacy in combination therapies and new targeted approaches for solid tumors.
